Background {#Sec1}
==========

Type 2 diabetes mellitus (T2DM) comprises 90% of people with diabetes around the world, and is largely the result of excess body weight and physical inactivity \[[@CR1]\]. Over the past decades, T2DM has become an epidemic \[[@CR2]\] and affects about 6% of the adult population in the western world \[[@CR3]\]. In Greece, the projected prevalence of T2DM in 2002 was estimated at 7.6% in men and 5.9% in women \[[@CR4]\].

T2DM is a costly disease. It is associated with significant burden due to specific diabetes-related microvascular complications, increased risk of macrovascular complications (ischemic heart disease, stroke and peripheral vascular disease), blindness, renal failure and amputations \[[@CR5]--[@CR7]\]. The American Diabetes Association (ADA) estimated the total cost of diabetes in the US at \$174 billion in 2007 \[[@CR8]\]. A recent Greek study estimated the total annual cost per patient for managing T2DM in Greece at €7111 \[[@CR9]\].

International guidelines recommend therapy in individuals with T2DM to target HbA1c ≤7% to minimize micro- and macrovascular risk \[[@CR10]\]. A target of HbA1c ≤6.5% may be considered in some patients with T2DM, but this must be balanced against the risk of hypoglycemic events \[[@CR11], [@CR12]\], which represent a significant economic burden \[[@CR13]\].

In a randomized, open-label, comparative study vildagliptin--metformin treatment provided blood glucose control efficacy comparable to that of glimepiride--metformin treatment and resulted in better adverse event profile with lower risks of hypoglycemia and weight gain \[[@CR14]\]. Another study showed that when metformin monotherapy fails to maintain sufficient glycaemic control, the addition of vildagliptin provides comparable efficacy to that of glimepiride, with a favourable safety profile and significant reduction in hypoglycaemia compared with glimepiride \[[@CR15]\].

Therefore, it was deemed necessary to investigate the additional costs associated with the additional benefits of vildagliptin--metformin in the management of T2DM, since payers are increasingly interested in the economic evaluation of new health technologies. This study aimed at assessing the cost effectiveness of vildagliptin versus glimepiride as add-on to metformin in the Greek healthcare setting.

Methods {#Sec2}
=======

Model design {#Sec3}
------------

A cost-effectiveness patient simulation model was developed in Excel^®^ based on the risk equations from the UK Prospective Diabetes Study (UKPDS) Outcomes model \[[@CR16]\]. During each cycle a patient could experience any of the following complications: ischemic heart disease, myocardial infarction, congestive heart failure, renal failure, stroke, amputation. The model is described in detail elsewhere \[[@CR17]\].

A cohort of 10,000 patients who failed to achieve glycemic control with metformin monotherapy entered the model. Baseline characteristics were assumed to be the same for both cohort models and were based on the Diabetes Atlas of the International Diabetes Federation \[[@CR18]\]. Mean patient age at model start was 63 years.

Two treatment strategies were compared in the model: strategy 1 in which vildagliptin is added to metformin in 2nd line treatment and strategy 2 in which glimepiride is added to metformin in 2nd line treatment (Table [1](#Tab1){ref-type="table"}). The HbA1c threshold (7%) based on which patients were switched to the next in line treatment was taken from the Hellenic Diabetes Association guidelines \[[@CR19]\].Table 1Treatment strategiesStrategy 1Strategy 21st line treatmentMetforminMetformin2nd line treatmentMetformin + vildagliptinMetformin + glimepiride3rd line treatmentMetformin + basal insulinMetformin + basal insulin4th line treatmentMetformin + intensive insulinMetformin + intensive insulin

The model's time horizon was that of a lifetime and outcomes assessment criteria were Quality Adjusted Life Years (QALYs) and Life Years (LYs). Future costs and outcomes were discounted at 3.5% per annum, since cost-effectiveness results should reflect the present value of the stream of costs and benefits accruing over the time horizon of the analysis \[[@CR20]\].

Model inputs {#Sec4}
------------

### Clinical data {#Sec5}

Clinical data on drugs' safety and efficacy, and in particular HbA1c reduction, changes in weight, and incidence rate of hypoglycemic events were extracted from a head-to-head clinical trial of vildagliptin and glimepiride in combination with metformin and a published meta-analysis of long-acting insulin analogues versus NPH human insulin \[[@CR15], [@CR21]\] (Table [2](#Tab2){ref-type="table"}). Outcomes data were extrapolated beyond the trial period with the use of the UKPDS model \[[@CR16]\].Table 2Efficacy and safety profiles of modelled interventionsMetformin^a^Meformin + glimepiride^a^Metformin + vildagliptin^a^Metformin + basal insulin^b^Metformin + intensive insulin^b^HbA1c initial absolute 1 year change−1.03−0.53−0.44−1.10−1.10Symptomatic Hypoglycaemia Risk (per year), %0.0016.201.6616.2016.20Severe Hypoglycaemia Risk (per year), %0.001.380.003.303.30Weight gain (kg/year)0.001.56-0.231.701.70^a^Source: Ferrannini et al. \[[@CR15]\]^b^Source: Monami et al. \[[@CR21]\]

### Cost data {#Sec6}

The model only considered direct medical costs, which consisted of pharmaceutical, adverse event and comorbidity costs. The perspective adopted was that of the Social Insurance Funds (SIFs) and the cost base year was 2014.

Drug unit costs were based on the Positive Reimbursement List \[[@CR22]\]. Annual costs were estimated based on daily dosages and frequency of administration included in the drugs' Summary of Product Characteristics (SPCs) (Table [3](#Tab3){ref-type="table"}).Table 3Drug costsAnnual cost (€)Metformin42.10Metformin + vildagliptin593.86Glimepiride35.83Metformin + glimepiride77.93Basal insulin539.16Metformin + basal insulin581.26Intensive insulin494.76Metformin + intensive insulin^a^1118.11^a^The cost of metformin + intensive insulin is calculated on top of the cost of metformin + basal insulin

The cost of monitoring insulin was based on the maximum number of glucose testing strips per patient per month and the respective prices reimbursed by the National Organization for Health Care Services Provision (EOPYY) \[[@CR23], [@CR24]\]. The annual cost for patients receiving insulin (basal or intensive) was estimated at €720, while the respective cost for patients on anti-diabetic treatment without receiving insulin was estimated at €180 (Table [4](#Tab4){ref-type="table"}).Table 4Insulin monitoring costs per yearMonitoring cost (€)Metformin180Meformin + glimepirideMetformin + vildagliptinMetformin + basal insulin720Metformin + intensive insulin

The unit costs associated with the management of diabetic complications during first year of treatment, including the cost of severe and non-severe hypoglycemia, were obtained from the Greek Diagnosis Related Groups (DRGs) tariffs \[[@CR25]\] and the study by Maniadakis and colleagues \[[@CR26]\] (Table [5](#Tab5){ref-type="table"}).Table 5First year and follow up costsFirst year event cost (€)Follow up costs after first year (€)SourceIschaemic heart disease1118933DRG code: N29M & calculations based on data from Maniadakis et al. \[[@CR26]\]Myocardial infarction (non fatal)27241542DRG code: K10X & calculations based on data from Maniadakis et al. \[[@CR26]\]Myocardial infarction (fatal)3924--DRG code: K10X + cost of death €1200 \[[@CR26]\]Congestive heart failure1868279DRG code: K42M & calculations based on data from Maniadakis et al. 2005 \[[@CR26]\]Stroke (non fatal)26252100DRG code: N30Mb & calculations based on data from Maniadakis et al. \[[@CR26]\]Stroke (fatal)2855--DRG codes: N30A + N30MaAmputation3608DRG code: K13MHypoglycemia (non-severe)50Based on clinical expert input (approx. the cost of a physician consultation)Hypoglycemia (severe)1735DRG code: Θ20ΜRenal failure36,02621,721Stafylas et al. \[[@CR28]\]

Patient follow-up costs after first year were all calculated based on data from the study by Maniadakis et al. \[[@CR26]\] and input from a clinical expert. The estimated costs were subsequently inflated with the Health Price Index \[[@CR27]\] to reflect 2014 prices. The cost of renal failure (€36,026 during first year and €21,721 after first year) was obtained from the study by Stafylas et al. \[[@CR28]\].

### Utility data {#Sec7}

The utility value for diabetic patients without complications (0.780), as well as the utility decrements relating to ischemic heart disease, myocardial infarction, congestive heart failure, stroke, and amputation were derived from the study by Clarke and colleagues \[[@CR29]\]. Disutility data associated with renal failure were obtained from the study by Manns et al. \[[@CR30]\], while respective data for weight increase were based on the Dennett et al. study \[[@CR31]\] (Table [6](#Tab6){ref-type="table"}).Table 6Utility decrementsEventValuesReferenceIschemic heart disease−0.090\[[@CR29]\]Myocardial infarction (non fatal)−0.055\[[@CR29]\]Congestive heart failure−0.108\[[@CR29]\]Stroke (non fatal)−0.164\[[@CR29]\]Amputation−0.280\[[@CR29]\]Renal failure−0.379\[[@CR30]\]Symptomatic hypoglycemia risk−0.014\[[@CR32]\]Severe hypoglycemia−0.047\[[@CR32]\]Weight increase (per kg)−0.002\[[@CR31]\]

Sensitivity analysis {#Sec8}
--------------------

In order to test the robustness of model results, univariate sensitivity analyses were conducted in key variables surrounded by uncertainty. In particular, the following variables were allowed to vary in ranges based on the literature: the HbA1c threshold (between 6.5 and 7.5% \[[@CR10]\]), utility and disutility scores (between 95% confidence intervals \[[@CR29]\]), and discount rates for costs and benefits (between 0 and 8% \[[@CR33]\]).

Results {#Sec9}
=======

The addition of vildagliptin to metformin (strategy 1) increased pharmaceutical cost compared with the addition of glimepiride to metformin (strategy 2) by €426 (from €2427 to €2853). However, this was offset by a decrease in the associated comorbidity and adverse event costs, resulting in a lower total cost in strategy 1 (€10,003) compared with strategy 2 (€10,077) (Table [7](#Tab7){ref-type="table"}).Table 7Mean per patient costsStrategy 1Strategy 2Pharmaceutical cost€2853€2427Comorbidities costs€4393€4539Ischaemic heart disease cost€371€ 343Myocardial infarction cost€1235€1242Congestive heart failure cost€340€316Stroke cost€1168€1186Amputation cost€36€30Renal failure cost€1243€1422Adverse events costs€2757€3111Non-severe hypoglycemia cost€19€29Severe hypoglycemia cost€126€179Monitoring costs€2611€2903Total costs€10,003€10,077

Comorbidity costs represented the largest cost component in both strategies (43.9 and 45.0% in strategies 1 and 2, respectively), while drug costs accounted for 28.5 and 24.1% of total costs in strategies 1 and 2, respectively (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1An overview of the model structure(Source: Clarke et al. \[[@CR16]\])

Apart from lower overall costs, strategy 1 was also associated with increased LYs (8.07 vs. 7.96 in strategy 2) and QALYs (6.30 vs. 6.19 in strategy 2) (Table [8](#Tab8){ref-type="table"}). Therefore, strategy 1 appears to be dominant, as it is associated with both lower overall costs and increased effectiveness (Fig. [2](#Fig2){ref-type="fig"}).Table 8Basecase resultsStrategy 1Strategy 2Difference (strategy 1 vs. strategy 2)Total costs€10,003€10,077−€74QALYs6.306.190.11Life years8.077.960.11ICER (cost per QALY gained)DominantICER (cost per LY gained)Dominant Fig. 2Cost breakdown

Sensitivity analysis results {#Sec10}
----------------------------

One-way sensitivity analysis confirmed dominance of vildagliptin in most variations of the parameters tested. Model results were most sensitive to changes in the HbA1c threshold. In particular, increasing the threshold from 7.0 to 7.5% resulted in vildagliptin being cost-effective rather than dominant, however with a very low incremental cost-effectiveness ratio (ICER = €1041 per QALY gained). Variations of disutility values for comorbidities did not impact significantly model results.

Discussion {#Sec11}
==========

T2DM is a chronic disease, with significant economic and social implications globally. It has been estimated that 347 million people suffer from diabetes worldwide \[[@CR34]\], and prevalence exhibits an increasing trend \[[@CR35]\]. The annual direct cost of T2DM in eight European countries was estimated at €29 billion, with an average cost per patient of €2834 \[[@CR36]\]. Therefore, the disease management armamentarium requires effective treatments that can control disease related expenditure. The present study assessed the costs and outcomes of adding vildagliptin to metformin in the management of T2DM in the Greek health care setting and showed that vildagliptin is associated with lower overall costs and increased health outcomes, both in terms of LYs and QALYs gained.

The study further showed that the largest cost component was the management of diabetes-related comorbidities, accounting for approx. 44% of total costs. This is confirmed by another Greek study which found that management of diabetes related comorbidities accounted for 48% of costs, while pharmaceutical treatment accounted for 35.9% \[[@CR9]\]. The high cost of managing diabetes comorbidities is further illustrated in the international literature. In the US, mean adjusted total costs for cardiac arrest episodes, cerebrovascular disease with stroke, hypoglycemia, complication, and renal failure episodes have been estimated at \$16,435; \$4558; \$445; \$5675 and \$8765, respectively \[[@CR37]\].

The second most significant cost component was the management of adverse events. Hypoglycemia is a common T2DM adverse events and is considered the key limiting step for optimizing glycemic control \[[@CR17]\]. The international literature has shown that both severe and non-severe hypoglycemia incur substantial healthcare costs, and failure to account for these costs may underestimate the value of management strategies that minimize hypoglycemia risk \[[@CR13]\]. In the Greek health care setting, severe hypoglycemia costs €1735 per event and is associated with an average hospitalization length of stay of 18 days \[[@CR25]\]. Based on the findings of the present study, adding vildagliptin to metformin is associated with reduced costs for both non-severe (by 34.5%) and severe (by 29.5%) hypoglycemia compared with adding glimepiride to metformin.

The present study had several limitations. First, patient demographics did not reflect the Greek diabetic patient population, but were based on global data. In addition, the model only direct costs were considered in the analysis, reflecting only partly the economic burden of the disease. The ADA has estimated that of the total cost associated with diabetes in the US, 66.7% is attributed to direct medical costs and 1/3 to reduced productivity \[[@CR8]\], thus indirect costs consist a significant cost component.

In addition, the current analysis did not incorporate a number of diabetes-related comorbidities, such as peripheral neuropathy, ulceration and blindness, which are expected to impact significantly the total burden of the disease. Therefore, we can argue that the estimated costs in this study underestimate true disease burden. However, it is expected that inclusion of these comorbidities would not have impacted differently the two model arms (strategy 1 vs. strategy 2), as these would increase proportionately the management cost in both arms, and therefore, would not change model results.

The model which was used in the current economic evaluation analysis has also run with cost inputs from the Portuguese health care setting, where it showed that vildagliptin as add on to metformin is a cost-effective treatment option \[[@CR17]\]. Adapting costs to the Greek health care system further favored vildagliptin. Such differences in the model outcomes are anticipated since both the resource use and related unit costs differ from country to country. This is confirmed by the INSTIGATE study, which estimated direct costs in five European countries and showed that the structure of direct cost varies considerably across countries, reflecting the differences in the management, resource use and prices across different health care systems \[[@CR38]\].

Decisions in health care need to be based on local data and methods that take into consideration all cost components and not just pharmaceutical costs. The present study showed that although the addition of vildagliptin to metformin increased pharmaceutical costs, it led to a reduction in the overall costs, due to the reduction in the other cost components. Thus, the cost-effectiveness approach implemented could be considered as appropriate, since it adequately represents the complete picture of disease burden in the local setting.

Conclusion {#Sec12}
==========

Vildagliptin as add-on treatment to metformin in the management of T2DM in Greece appears to be dominant versus glimepiride in terms of both cost per LY and cost per QALY gained. Decisions in health care need to be based on local data and methods that take into consideration all cost components and not just pharmaceutical costs. The present study satisfied both these criteria and produced strong results that should be taken into consideration in the decision making process by Health Authorities.
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